
Annual report 2021
added 12-23-2023
Neovasc Net Income 2011-2026 | NVCN
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Neovasc
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -24.9 M | -28.7 M | -35.1 M | -108 M | -22.9 M | -86.5 M | -26.7 M | -16.4 M | -6.34 M | -353 K | -3.78 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -353 K | -108 M | -32.7 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Medical devices industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Alphatec Holdings
ATEC
|
-143 M | $ 11.75 | -3.29 % | $ 1.76 B | ||
|
BioSig Technologies
BSGM
|
-10.3 M | - | 37.08 % | $ 85.7 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
-18.6 M | - | - | $ 1.77 B | ||
|
Axonics Modulation Technologies
AXNX
|
-59.7 M | - | - | $ 3.31 B | ||
|
Delcath Systems
DCTH
|
2.7 M | $ 8.98 | -1.32 % | $ 322 M | ||
|
Aziyo Biologics
AZYO
|
53.4 M | - | 1.37 % | $ 20.5 M | ||
|
Acutus Medical
AFIB
|
-81.7 M | - | -26.83 % | $ 2.62 M | ||
|
Allied Healthcare Products
AHPI
|
-1.94 M | - | 3.58 % | $ 2.21 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
-12.3 M | - | -5.86 % | $ 30.6 M | ||
|
Second Sight Medical Products
EYES
|
-23.5 M | - | -0.97 % | $ 54.4 M | ||
|
FONAR Corporation
FONR
|
12.4 M | $ 18.41 | 0.38 % | $ 121 M | ||
|
Conformis
CFMS
|
-50.5 M | - | - | $ 16.4 M | ||
|
Cardiovascular Systems
CSII
|
-36.9 M | - | 0.15 % | $ 844 M | ||
|
Inogen
INGN
|
-22.7 M | $ 6.32 | -2.02 % | $ 168 M | ||
|
Apollo Endosurgery
APEN
|
-39.8 M | - | - | $ 475 M | ||
|
IRIDEX Corporation
IRIX
|
-9.57 M | $ 1.35 | - | $ 21.8 M | ||
|
IRadimed Corporation
IRMD
|
22.5 M | $ 100.97 | 1.78 % | $ 1.28 B | ||
|
Avinger
AVGR
|
-18.3 M | - | -20.74 % | $ 369 K | ||
|
CryoLife, Inc.
CRY
|
-16.7 M | - | -4.14 % | $ 702 M | ||
|
LivaNova PLC
LIVN
|
-242 M | $ 62.4 | -1.33 % | $ 3.4 B | ||
|
LENSAR
LNSR
|
-31.4 M | $ 5.56 | -8.4 % | $ 64 M | ||
|
AxoGen
AXGN
|
-15.7 M | $ 32.61 | 2.71 % | $ 1.5 B | ||
|
CONMED Corporation
CNMD
|
47.1 M | $ 36.56 | -0.19 % | $ 1.13 B | ||
|
Medtronic PLC
MDT
|
4.66 B | $ 86.58 | -0.68 % | $ 111 B | ||
|
Soliton, Inc.
SOLY
|
-14.5 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
-9.14 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
-10.9 M | - | 0.03 % | $ 1.58 B | ||
|
NanoVibronix
NAOV
|
-3.7 M | - | - | $ 1.08 M | ||
|
Electromed
ELMD
|
7.54 M | $ 24.7 | 0.86 % | $ 209 M | ||
|
Misonix, Inc.
MSON
|
-17.4 M | - | - | $ 462 M | ||
|
InspireMD
NSPR
|
-48.8 M | $ 1.79 | 3.47 % | $ 115 M | ||
|
Orthofix Medical
OFIX
|
-92.2 M | $ 11.72 | -1.26 % | $ 464 M | ||
|
Intersect ENT, Inc.
XENT
|
-72.3 M | - | - | $ 955 M | ||
|
Cytosorbents Corporation
CTSO
|
-20.7 M | $ 0.7 | 3.3 % | $ 38.1 M | ||
|
Aethlon Medical
AEMD
|
-13.4 M | $ 2.16 | -6.09 % | $ 3.37 M | ||
|
Profound Medical Corp.
PROF
|
-30.7 M | $ 5.15 | -4.63 % | $ 180 M | ||
|
BIOLASE
BIOL
|
-20.6 M | - | -13.19 % | $ 166 K | ||
|
Penumbra
PEN
|
178 M | $ 334.17 | -0.41 % | $ 13 B | ||
|
AdaptHealth Corp.
AHCO
|
-70.8 M | $ 11.48 | 10.7 % | $ 1.55 B | ||
|
Myomo
MYO
|
-15.6 M | $ 0.7 | -1.83 % | $ 29.3 M | ||
|
Insulet Corporation
PODD
|
247 M | $ 225.5 | -0.7 % | $ 15.9 B | ||
|
Nano-X Imaging Ltd.
NNOX
|
-53.5 M | $ 2.4 | -1.64 % | $ 141 M | ||
|
Invacare Corporation
IVC
|
-20.6 M | - | - | $ 24.7 M | ||
|
EDAP TMS S.A.
EDAP
|
-19 M | $ 3.91 | 4.83 % | $ 146 M | ||
|
Quanterix Corporation
QTRX
|
-107 M | $ 3.82 | -3.05 % | $ 163 M | ||
|
OrthoPediatrics Corp.
KIDS
|
-39.6 M | $ 15.91 | -3.4 % | $ 373 M | ||
|
Outset Medical
OM
|
-81.7 M | $ 3.53 | -2.35 % | $ 53.7 K |